[1]
|
Abou, D.I., Jabbour, E., Short, N.J. and Ravandi, F. (2019) Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Current Treatment Options in Oncology, 20, Article No. 4.
https://doi.org/10.1007/s11864-019-0603-z
|
[2]
|
Terwilliger, T. and Abdul-Hay, M. (2017) Acute Lymphoblastic Leukemia: A Comprehensive Review and 2017 Update. Blood Cancer Journal, 7, e577. https://doi.org/10.1038/bcj.2017.53
|
[3]
|
郑智康, 黄健. 1例BCR/ABL P230阳性的慢性粒细胞白血病特殊骨髓形态报道[J]. 检验医学与临床, 2021, 18(23): 3500-3503.
|
[4]
|
Mesa, R.A., Jamieson, C., Bhatia, R., Deininger, M.W., Fletcher, C.D., Gerds, A.T., et al. (2017) NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. Journal of the National Comprehensive Cancer Network, 15, 1193-1207. https://doi.org/10.6004/jnccn.2017.0157
|
[5]
|
Martinelli, G., Boissel, N., Chevallier, P., Ottmann, O., Gökbuget, N., Topp, M.S., et al. (2017) Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment with Blina-tumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology, 35, 1795-1802. https://doi.org/10.1200/JCO.2016.69.3531
|
[6]
|
Stock, W., Martinelli, G., Stelljes, M., DeAngelo, D.J., Gökbuget, N., Advani, A.S., et al. (2021) Efficacy of Inotuzumab Ozogamicin in Patients with Philadelphia Chromosome-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia. Cancer, 127, 905-913. https://doi.org/10.1002/cncr.33321
|
[7]
|
赵美芳, 谭业辉. 成年人费城染色体阳性急性淋巴细胞白血病治疗现状及展望[J]. 白血病•淋巴瘤, 2020, 29(8): 509-512.
|
[8]
|
Couturier, M.A., Thomas, X., Raffoux, E., Huguet, F., Berthon, C., Simand, C., et al. (2021) Blinatumomab + Ponatinib for Relapsed/Refractory Philadelphia Chromo-some-Positive Acute Lymphoblastic Leukemia in Adults. Leukemia & Lymphoma, 62, 620-629. https://doi.org/10.1080/10428194.2020.1844198
|
[9]
|
Shen, S., Chen, X., Cai, J., Yu, J., Gao, J., Hu, S., et al. (2020) Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lympho-blastic Leukemia: A Randomized Clinical Trial. JAMA Oncology, 6, 358-366. https://doi.org/10.1001/jamaoncol.2019.5868
|
[10]
|
Rafei, H., Kantarjian, H.M. and Jabbour, E.J. (2019) Recent Advances in the Treatment of Acute Lymphoblastic Leukemia. Leukemia & Lymphoma, 60, 2606-2621. https://doi.org/10.1080/10428194.2019.1605071
|
[11]
|
Zhang, Y., Gao, Y., Zhang, H., Zhang, J., He, F., Hnízda, A., et al. (2018) PDGFRB Mutation and Tyrosine Kinase Inhibitor Resistance in Ph-Like Acute Lymphoblastic Leuke-mia. Blood, 131, 2256-2261.
https://doi.org/10.1182/blood-2017-11-817510
|
[12]
|
Sun, Y.Q., Li, S.Q., Zhao, X.S. and Chang, Y.J. (2020) Measurable Residual Disease of Acute Lymphoblastic Leukemia in Allograft Settings: How to Evaluate and Intervene. Expert Review of Anticancer Therapy, 20, 453-464.
https://doi.org/10.1080/14737140.2020.1766973
|
[13]
|
Li, J., Dai, Y., Wu, L., Zhang, M., Ouyang, W., Huang, J., et al. (2021) Emerging Molecular Subtypes and Therapeutic Targets in B-Cell Precursor Acute Lymphoblastic Leukemia. Frontiers of Medicine, 15, 347-371.
https://doi.org/10.1007/s11684-020-0821-6
|
[14]
|
Rabin, K.R. (2020) Optimizing Targeted Therapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. JAMA Oncology, 6, 333-334. https://doi.org/10.1001/jamaoncol.2019.5849
|
[15]
|
Warraich, Z., Tenneti, P., Thai, T., Hubben, A., Amin, H., McBride, A., et al. (2020) Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Phil-adelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review. Biology of Blood and Marrow Transplantation, 26, e55-e64.
https://doi.org/10.1016/j.bbmt.2019.09.022
|